Skip to main content

The Globe and Mail

Three companies voluntarily recall antipsychotic drug quetiapine

Health Canada says three companies are voluntarily recalling all lots of the antipsychotic drug quetiapine.

A Health Canada news release says it's due to potential contamination with the antibiotic product clindamycin during the manufacturing process.

Health Canada says quetiapine is used in the treatment of schizophrenia and bipolar disorder in adult patients.

Story continues below advertisement

Health Canada says it has not received any reports of adverse reactions from the product.

The government says those at risk includes people who are susceptible or hypersensitive to the antibiotics clindamycin or lincomycin, but estimates the number of patients in question is small.

Health Canada says the possibility of contamination was spotted at the pharmaceutical factory in China that produces quetiapine for the three companies – Cobalt Pharmaceuticals Company, Laboratoires Riva Inc. and Sanis Health Inc.

Health Canada says the products affected include all lots of 25 mg, 100 mg, 200 mg and 300 mg doses of Co Quetiapine (Cobalt Pharmaceuticals Company), Riva Quetiapine (Laboratoires Riva Inc.), and Sanis Quetiapine (Sanis Health Inc.)

Health Canada said in an e-mail that the recall represents less than 25 per cent of the quetiapine marketed in Canada.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at